



STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: Noroxymorphone

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled [checked]
Not Controlled [unchecked]

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

- The substance is a metabolite of oxymorphone and included under item 1 of Schedule I to the CDSA.

Prepared by: Evelyn Soo Date: Dec 2nd 2010

Verified by: Marianne Tang Date:

Approved by: DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES Date:

This status was requested by: Wissam Sader

## Drug Status Report


**Drug:** Noroxymorphone

**Drug Name Status:** Noroxymorphone is the common name.

**Chemical Name:** 5alpha-4,5-Epoxy-3,14-dihydroxymorphinan-6-one

**Other Names:** 14-Hydroxydihydromorphinone; 7,8-Dihydro-14-hydroxynormorphinone

**Chemical structure:**



**Molecular Formula:** C<sub>16</sub>H<sub>17</sub>NO<sub>4</sub>

**CAS-RN:** 33522-95-1

**Pharmacological class / Application:** Metabolite of oxymorphone

**International status:**

US: Noroxymorphone is not listed in the schedules to the CSA and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances Under International Control.

Canadian Status: Noroxymorphone is a metabolite of oxymorphone<sup>1</sup> and is not currently listed in the CDSA. However, as a metabolite of oxycodone, the substance must be included under item 1(28) of Schedule I, under the heading "Opium poppy (*Papaver somniferum*) its preparations, derivatives, alkaloids and salts, including:" as a derivative of oxycodone.

**Recommendation:** Noroxymorphone is included under item 1(28) of Schedule I to the CDSA and is a controlled substance.

---

<sup>1</sup>Samer, CF. (2010) The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone, Br. J. Pharmacol. **160**: 907-918.

**Date:** 2 December 2010